Abstract
Background
We investigated the clinical effectiveness of fenofibrate or omega 3-fatty acid in patients with diabetes for long term.
Methods
Using Korean National Health Insurance data base, 141972 eligible patients with diabetes were selected. We divided the patients into 2 groups with propensity matching 1:2 ratio, fenofibrate/omega 3 fatty acid users (Fen-O, n=42353) or no users (n=14880). We followed up for 6-years for primary endpoint of death, myocardial infarction (MI), stroke and individual outcomes including cardiac death.
Results
Primary endpoint was significantly lower in Fen-O group as compared to no users, 2.35% vs. 1.58% (HR 0.673, CI: 0.633–0.715, P<0.001) in crude and 2.35% vs. 1.58% (HR 0.641, CI: 0.565–0.728) after adjusting age, sex, medical history analysis, body mass index, LDL-C and HDL-C). All cause death (0.76% vs. 1.24% [HR 0.664, CI: 0.625–0.706], p<0.0001), cardiac death (0.11% vs. 1.19% [HR 0.610, CI: 0.486–0.765, p=0.0001) and stroke (0.57% vs. 0.79%, [HR 0.723, CI: 0.594–0.881, P=0.0013) were significantly lower in Fen-O group. In the survival analysis, Fen-O group showed significantly lower primary outcome rate which is proportional with the days of intaking fenofibrate or omega 3 fatty acid (log rank <0.001),
Conclusions
Use of fenofibrate or omega 3 fatty-acid was associated with lower rate of composite of death, MI, stroke in diabetes patient for 6 year follow-up with large population.
Funding Acknowledgement
Type of funding source: None
Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort
